BACKGROUND: F-PSMA-1007 PET/CT in PCa staging to provide evidence-based data in this setting. METHODS: F-PSMA-1007 PET/CT in PCa staging was performed until 31 December 2020. Eligible articles were selected and relevant information was extracted from the original articles by two authors independently. RESULTS: F-PSMA-1007-PET/CT may detect metastatic disease in a significant number of patients with negative standard imaging. CONCLUSIONS: F-PSMA-1007 PET/CT demonstrated a good accuracy in PCa staging, with similar results compared with other PSMA-targeted radiopharmaceuticals. This method could substitute bone scintigraphy and conventional abdominal imaging for PCa staging. Prospective multicentric studies are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Awenat et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: